2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers Lain Anderson TJ Bilodeau Read more
Related Practice Life Sciences & Pharma In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations. 01052021090143
Published Articles Life Sciences & Pharma The Growth of Radiotherapeutics: Addressing Supply Chain Complexity May 21, 2025
Executive Insights Life Sciences & Pharma Advanced In Vitro Models: Opportunities and Challenges for US Drug Development May 7, 2025
Executive Insights Life Sciences & Pharma Quantum Computing in Biopharma: Future Prospects and Strategic Insights May 1, 2025
Case Study Life Sciences & Pharma Building Resilience in a Commercial-Stage Pharma Company’s Supply Chain April 16, 2025
Executive Insights Life Sciences & Pharma Aligning Aseptic Fill/Finish Operations With Global Pharmaceutical Demand February 3, 2025